Join Foundation Medicine at the Specialty Networks National Urology Conference

Foundation Medicine is delighted to be attending the Specialty Networks National Urology Conference – Fall 2024 in Phoenix, Arizona, September 19-20.

We look forward to connecting with the Urology community soon, sharing how comprehensive genomic profiling (CGP) can guide care for advanced prostate cancer patients and why all CGP tests are not created equal.

Unlock the Right Treatment Options for Your Patients with Advanced Prostate Cancer

Ask us:

What emerging biomarkers can be identified by a clinically validated liquid biopsy test?
About the connection between PSA levels and ctDNA tumor fraction.*
How can you integrate Foundation Medicine’s CGP tests within PPS Analytics?

Foundation Medicine can help provide your patients more treatment options by identifying guideline-recommended FDA-approved therapies.

If you plan on attending the conference, please stop by the Foundation Medicine booth to meet our team. Click here to schedule a meet and greet with our team during the conference.

Meet with our team at Specialty Networks National Urology Conference

*Foundation Medicine’s ctDNA tumor fraction is a determination of the amount of circulating tumor DNA as a fraction of total cell free DNA in a blood sample that accounts for aneuploidy,
variant allele frequency, fragment length information, clonal hematopoiesis predictions and known tumor-associated alterations. ctDNA tumor fraction is reported as a laboratory professional service which has not been reviewed or approved by the FDA.